Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

• Yutaka Fujiwara ,

  * E-mail: yutakafu@ncc.go.jp

  Affiliations Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan, Division of Investigational Cancer Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital, Chiba, Japan

  ⨯
• Masanori Toyoda,

  Affiliation Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Naoko Chayahara,

  Affiliation Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Naomi Kiyota,

  Affiliation Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Takanobu Shimada,

  Affiliation Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Yoshinori Imamura,

  Affiliation Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Toru Mukohara,

  Affiliations Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan, Cancer Center, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯
• Hironobu Minami

  Affiliations Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Japan, Cancer Center, Kobe University Graduate School of Medicine, Kobe, Japan

  ⨯